Theravance Biopharma Inc (TBPH) Earnings History
Profitable15 years of earnings data (2011–2025) · Positive TTM net income
Loading earnings history...
Theravance Biopharma Inc (TBPH) Earnings Overview
As of October 3, 2026, Theravance Biopharma Inc (TBPH) reported trailing twelve-month net income of $54M, reflecting +279.1% year-over-year growth. The company earned $1.04 per diluted share over the past four quarters, with a net profit margin of 98.5%.
Looking at the long-term picture, TBPH's historical earnings data spans multiple years. The company achieved its highest annual net income of $872M in fiscal 2022.
Theravance Biopharma Inc maintains industry-leading profitability with a gross margin of 94.9%, operating margin of -12.3%, and net margin of 98.5%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including INVA ($357M net income, 63.8% margin), PRGO (-$1.73B net income, -33.5% margin), SUPN (-$110M net income, -5.4% margin), TBPH has outperformed on profitability metrics. Compare TBPH vs INVA →
TBPH Earnings vs Peers
Earnings metrics vs comparable public companies
TBPH Historical Earnings Data (2011–2025)
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $106M | +287.7% | -$13M | $2.06 | 98.5% | -12.3% |
| 2024 | -$56M | -2.2% | -$47M | $-1.15 | -87.6% | -72.9% |
| 2023 | -$55M | -106.3% | -$56M | $-1.00 | -96.1% | -97.6% |
| 2022 | $872M | +537.3% | -$92M | $-1.26 | 1698.5% | -179.1% |
| 2021 | -$199M | +28.3% | -$258M | $-2.87 | -360.6% | -466.1% |
| 2020 | -$278M | -17.6% | -$298M | $-4.46 | -386.9% | -414.2% |
| 2019 | -$236M | -9.7% | -$252M | $-4.25 | -322.1% | -343.1% |
| 2018 | -$216M | +24.5% | -$239M | $-3.99 | -357.0% | -395.5% |
| 2017 | -$285M | -49.7% | -$260M | $-5.45 | -1855.0% | -1690.6% |
| 2016 | -$191M | -4.6% | -$180M | $-4.26 | -391.9% | -371.0% |
| 2015 | -$182M | +23.1% | -$182M | $-5.34 | -432.6% | -431.8% |
| 2014 | -$237M | -51.7% | -$233M | $-7.46 | -2028.0% | -1989.6% |
| 2013 | -$156M | -1532.2% | -$156M | $-4.84 | -69152.2% | -69152.2% |
| 2012 | -$10M | +91.2% | -$10M | $-0.30 | -7.4% | -7.4% |
| 2011 | -$109M | - | -$109M | $-3.43 | -736.1% | -736.1% |
Download Data
Export TBPH earnings history in CSV or JSON format
Free sign-in required to download data
TBPH Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TBPH — Frequently Asked Questions
Quick answers to the most common questions about buying TBPH stock.
What is TBPH earnings per share (EPS)?
TBPH trailing twelve-month (TTM) diluted EPS is $1.04, reflecting +279.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2025 is available in the table on this page.
What is Theravance Biopharma Inc's net income?
Theravance Biopharma Inc (TBPH) trailing twelve-month net income is $54M as of 2025. Earnings grew +279.1% year-over-year.
Is TBPH profitable?
Yes, TBPH is profitable with a TTM net income of $54M and a net profit margin of +98.5%.
What is TBPH's earnings growth rate?
TBPH compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2025.
What are TBPH's profit margins?
Theravance Biopharma Inc net profit margin is +98.5%, operating margin is -12.3%, and gross margin is +94.9%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +44.8%.
Is TBPH growing earnings?
Yes, TBPH earnings are accelerating — EPS growth of +279.1% exceeds the 5-year CAGR of N/A. TTM net income reached $54M. Earnings momentum is strengthening.
What was TBPH's best earnings year?
Theravance Biopharma Inc's highest annual net income on record is $872M, achieved in fiscal year 2022. Earnings history on this page spans 2011 to 2025 and includes all annual and quarterly figures.
What were TBPH's earnings last quarter?
TBPH's most recent reported quarter was Q2 2026. Net income was $-6M with diluted EPS of $-0.11. For a full breakdown of all quarters, see the quarterly earnings table on this page.